© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Expert Interviews
Nearly 40% of women in perimenopause feel misdiagnosed as clinicians fail to recognize the early stage of transition, treating anxiety over hormones while symptoms worsen.
Experts discuss the utility of the STOP-Bang questionnaire as a simple, sensitive screening tool for obstructive sleep apnea (OSA) in primary care, highlighting its strengths and limitations, the importance of clinical judgment in interpreting results, and the value of complementary tools such as the Epworth Sleepiness Scale in supporting a comprehensive, patient-centered approach to OSA diagnosis and management.
Experts discuss the widespread underdiagnosis of obstructive sleep apnea (OSA), emphasizing its significant impact on quality of life and comorbid conditions, the critical role of primary care in early detection, the importance of family input in recognizing symptoms, and the need for proactive, multidisciplinary strategies to ensure timely diagnosis and effective management.
Clevenger, a professor of nursing at Emory University, shares practical strategies to manage agitation in Alzheimer disease, emphasizing that this symptom is treatable.
Panelists discuss how NK1 receptor antagonists show promise beyond VMS, suggesting wider therapeutic potential across neurological and systemic conditions.
Panelists discuss how NK receptor antagonists deliver fast symptom relief with strong safety profiles, improving adherence and clinical confidence in their use.
Nearly one-third of caregivers hesitate to discuss agitation in a patient with AD. Emory's Clevenger, shares why and how clinicians can proactively address this barrier.
Emory's Clevenger discusses the neurotransmitter dysregulation behind agitation in AD and why memory-focused care doesn't address behavioral symptoms.
Clevenger reviews survey findings behind the recent report "The Agitation Blindspot in Alzheimer’s Care."
Panelists discuss how elinzanetant offers a safe, effective nonhormonal option for managing VMS in women receiving endocrine therapy for breast cancer.